FRONTIER BIOTECHNOLOGIES Inc.

Press Releases

   
Home>Media

Frontier Enters Into A New Partnership With Avacare Health To Continue Its Global Expansion Into East And West Africa

Frontier Biotechnologies Inc. (Frontier) is pleased to announce our partnership with Avacare Health Group (Avacare Health) to expand access for Albuvirtide to people living with HIV (PLHIV) in Kenya, Nigeria, Tanzania and Malawi, thus reaching the key countries in eastern and western Africa.There ar...
  • 2022-07-25  15:45:07
details>

Aikening®(Albuvirtide) is a Recommended Regimen for Post-Exposure AIDS Patients in the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2021 Edition)

In October 2021, in the “13th National AIDS and Hepatitis C Conference of the Chinese Medical Association”, organized by the AIDS Group of the Chinese Society of Infectious Diseases, Chinese Medical Association, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2021 Edition) (hereinaft...
  • 2022-07-05  15:42:55
details>

Aikening® Brings about A New Anti-HIV Combination Therapy! Results of Phase III Clinical Study TALENT Launched in IAS

On July 18, 2021 local time, the 11th International AIDS Society (IAS) Conference on HIV Science was held in Berlin, Germany. At this conference, Frontier Biotech (stock code: 688221.SH) released the key research results of its Phase III clinical study (TALENT study) on the long-acting anti-HIV-1 fu...
  • 2022-07-05  15:39:10
details>

Results of Phase III TALENT Study on Frontier Biotech’s Long-acting Anti-HIV Fusion Inhibitor Albuvirtide Were Published in An Authoritative International Medical Journal

On June 10, 2022, the Journal Of Infection (ISSN: 0163-4453, eISSN: 1532-2742), an authoritative international medical journal, published online the 48-week final results of Phase III clinical TALENT study on Frontier Biotech’s long-acting anti-HIV fusion inhibitor Albuvirtide (ABT). In 2018, based ...
  • 2022-06-22  15:36:07
details>

Aikening® Launch in Azerbaijan

Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual th...
  • 2022-06-22  10:08:57
details>

An Investigator Initiated Clinical Trial of Inhaled Bofutrelvir for Post-Exposure Prophylaxis in Close Contacts of COVID-19 Patients

Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, m...
  • 2022-06-15  10:08:28
details>

FB2001 (Bofutrelvir) Phase II/III Clinical Trial Protocol Approved by NMPA

Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to ev...
  • 2022-04-27  10:07:38
details>

Frontier Biotech opens a new manufacture facility in Chengdu ——Aikening ®, a novel long-acting HIV medicine, receives a production capability boost

On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang.Aiming at intelligent manufacturing, high efficiency and eco syst...
  • 2021-08-31  16:54:43
details>

Frontier Biotech Completes IPO on Shanghai Stock Exchange

Nanjing, China, October 28, 2020 -- Frontier Biotechnologies Inc.( Frontier Biotech), a commercial-stage biopharmaceutical company focused on discovering, development, manufacturing, and commercialization of innovative medicines, today announced its completion of the Initial Public Offering (IPO) an...
  • 2020-10-28  09:04:39
details>

Frontier Biotech partners with R-pharm to provide Aikening® to Russian patients

July 21, 2021 Nanjing, China. Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global H...
  • 2021-08-30  15:52:59
details>

Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

  • 2021-08-11  11:42:43
details>

AikeningTM (AlfusidTM) Marketing Authorization Granted by the Ministry of Health of Ecuador

Frontier Biotech (688221.SH) recently received the Certificate of Registration of Foreign Medicines issued by the Ministry of Health of Ecuador for companys innovative anti-HIV drug AikeningTM (Albuvirtide for injection 160 mg) to be marketed in Ecuador.AlfusidTM is the registered trade mark of Aike...
  • 2021-03-18  19:58:20
details>

Develop Innovative Therapies to Better Human Lives

Frontier Biotechnologies Inc.（Nanjing）
Medicalinfo@frontierbiotech.com
jubao@frontierbiotech.com
Adverse events report mailbox：pv@frontierbiotech.com
Copyright © 2016 Corporation All Rights ReservedFrontier Biotechnologies Inc.
Full Prescribing Information | Introduction for Use | About Frontier

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

I am a licensed Healthcare Professional I am a Patient or Caregiver